Grace Therapeutics, Inc. (GRCE) 10-Year Financial Performance & Capital Metrics

GRCE • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutGrace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.Show more

Revenue $0
EBITDA -$17M -47.5%
Net Income -$10M +25.6%
EPS (Diluted) -0.79 +54.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -14.91% +24.8%
ROIC -30.06% -40.5%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 62.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM32.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM51.37%

ROCE

10Y Avg-62.01%

5Y Avg-30.11%

3Y Avg-30.26%

Latest-23.54%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Feb 2015	Feb 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	216.29K	27.79K	0	0	0	196K	0	0	0	0
Revenue Growth %	-0.52%	-0.87%	-1%	-	-	-	-1%	-	-	-
Cost of Goods Sold+	187.9K	60.08K	0	0	0	76K	0	0	11K	0
COGS % of Revenue	0.87%	2.16%	-	-	-	0.39%	-	-	-	-
Gross Profit+	28.39K	-32.29K	0	0	0	120K	0	0	-11K	0
Gross Margin %	0.13%	-1.16%	-	-	-	0.61%	-	-	-	-
Gross Profit Growth %	-0.85%	-2.14%	1%	-	-	-	-1%	-	-	1%
Operating Expenses+	9.72M	7.03M	15.25M	34.41M	24.44M	16.54M	15.59M	52.16M	11.3M	16.68M
OpEx % of Revenue	44.94%	253.1%	-	-	-	84.38%	-	-	-	-
Selling, General & Admin	2.86M	1.51M	3.12M	4.29M	8.46M	6.66M	9.78M	8.21M	6.67M	7.16M
SG&A % of Revenue	13.2%	54.34%	-	-	-	33.95%	-	-	-	-
Research & Development	7.05M	5.58M	12.13M	29.37M	15.97M	4.17M	5.56M	9.97M	4.63M	9.51M
R&D % of Revenue	32.6%	200.92%	-	-	-	21.29%	-	-	-	-
Other Operating Expenses	-188K	-60.08K	0	741K	0	5.71M	249K	33.97M	0	7K
Operating Income+	-9.91M	-7.09M	-15.25M	-34.41M	-24.44M	-16.42M	-15.59M	-52.16M	-11.31M	-16.68M
Operating Margin %	-45.8%	-255.26%	-	-	-	-83.77%	-	-	-	-
Operating Income Growth %	-0.02%	0.28%	-1.15%	-1.26%	0.29%	0.33%	0.05%	-2.35%	0.78%	-0.47%
EBITDA+	-8.04M	-5.33M	-13.18M	-32.07M	-22.12M	-15.49M	-15.34M	-52.03M	-11.3M	-16.67M
EBITDA Margin %	-37.18%	-191.67%	-	-	-	-79.06%	-	-	-	-
EBITDA Growth %	0.01%	0.34%	-1.48%	-1.43%	0.31%	0.3%	0.01%	-2.39%	0.78%	-0.48%
D&A (Non-Cash Add-back)	1.87M	1.77M	2.07M	2.33M	2.32M	924K	0	124K	11K	7K
EBIT	-9.91M	-4.66M	-16.37M	-39.09M	-25.27M	-10.72M	-15.34M	-18.25M	-14.63M	-16.68M
Net Interest Income+	66.34K	52.39K	-1.11M	-427K	43K	-157K	77K	246K	911K	711K
Interest Income	69.53K	53.87K	55.75K	358K	336K	107K	77K	246K	911K	711K
Interest Expense	3.24K	1.48K	283.41K	278K	293K	264K	0	0	0	0
Other Income/Expense	8.58M	2.43M	-1.4M	-4.96M	-1.07M	-3.26M	5.12M	184K	-3.32M	3.91M
Pretax Income+	-1.32M	-4.66M	-16.65M	-39.37M	-25.51M	-19.68M	-10.47M	-51.97M	-14.63M	-12.77M
Pretax Margin %	-6.12%	-167.78%	-	-	-	-100.4%	-	-	-	-
Income Tax+	0	0	0	0	0	0	-648K	-9.54M	-1.78M	-3.2M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.94%	0.82%	0.88%	0.75%
Net Income+	-1.32M	-4.66M	-16.65M	-39.37M	-25.51M	-19.68M	-9.82M	-42.43M	-12.85M	-9.57M
Net Margin %	-6.12%	-167.78%	-	-	-	-100.4%	-	-	-	-
Net Income Growth %	0.87%	-2.52%	-2.57%	-1.36%	0.35%	0.23%	0.5%	-3.32%	0.7%	0.26%
Net Income (Continuing)	-1.32M	-4.66M	-16.65M	-39.37M	-25.51M	-19.68M	-9.82M	-42.43M	-12.85M	-9.57M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-9.59	-27.94	-58.96	-46.90	-14.40	-7.98	-1.60	-5.71	-1.73	-0.79
EPS Growth %	0.86%	-1.91%	-1.11%	0.2%	0.69%	0.45%	0.8%	-2.57%	0.7%	0.54%
EPS (Basic)	-9.59	-27.94	-58.96	-46.90	-14.40	-7.98	-1.60	-5.71	-1.73	-0.79
Diluted Shares Outstanding	221.2K	222.08K	364.3K	1.13M	1.76M	2.47M	6.14M	7.43M	7.44M	12.09M
Basic Shares Outstanding	221.2K	222.08K	364.3K	1.13M	1.76M	2.47M	6.14M	7.43M	7.44M	12.09M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Feb 2015	Feb 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	15.7M	8.36M	7.35M	27.97M	15.96M	62.37M	45.53M	29.29M	24.01M	22.71M
Cash & Short-Term Investments	14.69M	7.73M	6.37M	25.76M	14.24M	60.73M	43.66M	27.89M	23M	22.13M
Cash Only	1.05M	2.23M	6.37M	16.87M	14.24M	50.94M	30.34M	27.88M	23M	22.13M
Short-Term Investments	13.64M	5.49M	0	8.89M	0	9.79M	13.32M	15K	0	0
Accounts Receivable	682.99K	294.44K	587.73K	1.19M	546K	530K	548K	802K	722K	126K
Days Sales Outstanding	1.15K	3.87K	-	-	-	986.99	-	-	-	-
Inventory	69.83K	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	135.65	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	80.53K	183K	195K	768K	602K	0	0	0
Total Non-Current Assets+	14.04M	12.69M	10.43M	8.93M	6.89M	86K	83.09M	49.83M	49.29M	49.28M
Property, Plant & Equipment	55.9K	211.79K	2.18M	2.11M	2.06M	86K	315K	567K	24K	15K
Fixed Asset Turnover	3.87x	0.13x	-	-	-	2.28x	-	-	-	-
Goodwill	0	0	0	0	0	0	12.96M	8.14M	8.14M	8.14M
Intangible Assets	13.98M	11M	7.79M	6.39M	4.24M	0	69.81M	41.13M	41.13M	41.13M
Long-Term Investments	0	0	20.13K	20K	0	0	0	0	0	0
Other Non-Current Assets	0	1.48M	429.76K	417K	594K	0	0	0	0	0
Total Assets+	29.74M	21.04M	17.78M	36.9M	22.85M	62.46M	128.62M	79.12M	73.3M	71.99M
Asset Turnover	0.01x	0.00x	-	-	-	0.00x	-	-	-	-
Asset Growth %	-0.27%	-0.29%	-0.16%	1.08%	-0.38%	1.73%	1.06%	-0.38%	-0.07%	-0.02%
Total Current Liabilities+	1.3M	842K	5.19M	13.67M	7.39M	1.58M	3.26M	3.41M	1.68M	1.93M
Accounts Payable	197.03K	276.73K	2.65M	3.05M	0	115K	3.16M	1.24M	1.01M	601K
Days Payables Outstanding	382.74	1.68K	-	-	-	552.3	-	-	33.41K	-
Short-Term Debt	0	0	0	1.36M	76K	86K	104K	75K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	5.96M	607K	0	946K	0	0
Current Ratio	12.11x	9.93x	1.42x	2.05x	2.16x	39.50x	13.97x	8.59x	14.26x	11.77x
Quick Ratio	12.05x	9.93x	1.42x	2.05x	2.16x	39.50x	13.97x	8.59x	14.26x	11.77x
Cash Conversion Cycle	905.5	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.88M	115.12K	6.22M	12.18M	2.46M	5.22M	17.09M	7.76M	9.87M	3.45M
Long-Term Debt	0	0	1.25M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	71K	0	191K	410K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	16.89M	7.35M	5.51M	2.31M
Other Non-Current Liabilities	1.88M	115.12K	4.98M	12.18M	2.39M	5.22M	10K	0	4.36M	1.14M
Total Liabilities	3.18M	957.12K	11.41M	25.85M	9.86M	6.8M	20.35M	11.17M	11.56M	5.38M
Total Debt+	0	0	1.25M	1.36M	147K	86K	295K	485K	0	0
Net Debt	-1.05M	-2.23M	-5.12M	-15.51M	-14.09M	-50.86M	-30.04M	-27.39M	-23M	-22.13M
Debt / Equity	-	-	0.20x	0.12x	0.01x	0.00x	0.00x	0.01x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3053.95x	-4805.56x	-53.82x	-123.76x	-83.41x	-62.19x	-	-	-	-
Total Equity+	26.56M	20.09M	6.37M	11.04M	12.99M	55.66M	108.27M	67.95M	61.74M	66.61M
Equity Growth %	-0.11%	-0.24%	-0.68%	0.73%	0.18%	3.28%	0.95%	-0.37%	-0.09%	0.08%
Book Value per Share	120.06	90.45	17.48	9.77	7.37	22.53	17.63	9.14	8.30	5.51
Total Shareholders' Equity	26.56M	20.09M	6.37M	11.04M	12.99M	55.66M	108.27M	67.95M	61.74M	66.61M
Common Stock	49.26M	45.73M	56.79M	110.86M	137.42M	197.19M	257.99M	258.29M	261.04M	1K
Retained Earnings	-26.62M	-29.24M	-56.05M	-100.83M	-126.34M	-146.02M	-155.84M	-198.27M	-211.12M	-220.69M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	-7.89M	-6.33M	-6.04M	-6.04M	-6.04M	-6.04M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Feb 2015	Feb 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-5.75M	-4.85M	-9.69M	-24.79M	-22.95M	-14.32M	-17.23M	-15.91M	-12.33M	-14.9M
Operating CF Margin %	-26.6%	-174.59%	-	-	-	-73.06%	-	-	-	-
Operating CF Growth %	0.06%	0.16%	-1%	-1.56%	0.07%	0.38%	-0.2%	0.08%	0.22%	-0.21%
Net Income	-1.32M	-4.66M	-16.65M	-39.37M	-25.51M	-19.68M	-9.82M	-42.43M	-12.85M	-9.57M
Depreciation & Amortization	1.87M	1.77M	2.07M	2.33M	2.32M	924K	0	124K	11K	7K
Stock-Based Compensation	1.24M	228.03K	719.37K	777K	1.95M	1.17M	1.34M	1.81M	913K	730K
Deferred Taxes	0	0	0	0	0	0	-648K	-9.54M	-1.83M	-3.2M
Other Non-Cash Items	-8.58M	-2.15M	1.39M	5.28M	1.51M	9.21M	-5.32M	33.94M	2.71M	-3.22M
Working Capital Changes	1.04M	-30.25K	2.77M	6.19M	-3.22M	-5.95M	-2.79M	181K	-1.28M	342K
Change in Receivables	235.78K	336.5K	-428.21K	-620K	581K	58K	-18K	-302K	80K	596K
Change in Inventory	139.07K	64.94K	0	0	0	0	0	0	0	0
Change in Payables	-69.52K	36.94K	0	0	0	0	0	0	0	0
Cash from Investing+	6.1M	6.07M	-318.26K	-9.44M	8.14M	-9.86M	-3.52M	13.15M	104K	0
Capital Expenditures	-27.97K	-203.67K	-352.33K	-534K	-319K	-69K	0	-17K	-22K	0
CapEx % of Revenue	0.13%	7.33%	-	-	-	0.35%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-7.99K	16.23K	54.2K	0	0	0	0	0	111K	0
Cash from Financing+	36.77K	-2.21K	8.83M	45.69M	13.18M	59.49M	0	304K	7.36M	14.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	36.77K	-2.21K	295.03K	798K	7.76M	158K	0	0	-141K	-967K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.82M	-5.12M	-10.05M	-25.32M	-23.27M	-14.39M	-17.23M	-15.93M	-12.36M	-14.9M
FCF Margin %	-26.92%	-184.36%	-	-	-	-73.41%	-	-	-	-
FCF Growth %	0.07%	0.12%	-0.96%	-1.52%	0.08%	0.38%	-0.2%	0.08%	0.22%	-0.21%
FCF per Share	-26.32	-23.07	-27.58	-22.39	-13.21	-5.82	-2.81	-2.14	-1.66	-1.23
FCF Conversion (FCF/Net Income)	4.35x	1.04x	0.58x	0.63x	0.90x	0.73x	1.76x	0.38x	0.96x	1.56x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-4.69%	-19.99%	-125.89%	-452.14%	-212.26%	-57.33%	-11.98%	-48.15%	-19.82%	-14.91%
Return on Invested Capital (ROIC)	-27.11%	-24.54%	-119.77%	-	-	-664.74%	-28.16%	-65.86%	-21.4%	-30.06%
Gross Margin	13.13%	-116.22%	-	-	-	61.22%	-	-	-	-
Net Margin	-611.68%	-16777.63%	-	-	-	-10039.8%	-	-	-	-
Debt / Equity	-	-	0.20x	0.12x	0.01x	0.00x	0.00x	0.01x	-	-
Interest Coverage	-3053.95x	-4805.56x	-53.82x	-123.76x	-83.41x	-62.19x	-	-	-	-
FCF Conversion	4.35x	1.04x	0.58x	0.63x	0.90x	0.73x	1.76x	0.38x	0.96x	1.56x
Revenue Growth	-51.95%	-87.15%	-100%	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Grace Therapeutics, Inc. (GRCE) grew revenue by 0.0% over the past year. Growth has been modest.

Grace Therapeutics, Inc. (GRCE) reported a net loss of $7.8M for fiscal year 2025.

Dividend & Returns

Grace Therapeutics, Inc. (GRCE) has a return on equity (ROE) of -14.9%. Negative ROE indicates the company is unprofitable.

Grace Therapeutics, Inc. (GRCE) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Grace Therapeutics, Inc. (GRCE) 10-Year Financial Performance & Capital Metrics

GRCE • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$17M -47.5%
Net Income -$10M +25.6%
EPS (Diluted) -0.79 +54.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -14.91% +24.8%
ROIC -30.06% -40.5%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 62.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM32.63%

EPS CAGR

10Y-

5Y-

3Y-

TTM51.37%

ROCE

10Y Avg-62.01%

5Y Avg-30.11%

3Y Avg-30.26%

Latest-23.54%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Feb 2015	Feb 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	216.29K	27.79K	0	0	0	196K	0	0	0	0
Revenue Growth %	-0.52%	-0.87%	-1%	-	-	-	-1%	-	-	-
Cost of Goods Sold+	187.9K	60.08K	0	0	0	76K	0	0	11K	0
COGS % of Revenue	0.87%	2.16%	-	-	-	0.39%	-	-	-	-
Gross Profit+	28.39K	-32.29K	0	0	0	120K	0	0	-11K	0
Gross Margin %	0.13%	-1.16%	-	-	-	0.61%	-	-	-	-
Gross Profit Growth %	-0.85%	-2.14%	1%	-	-	-	-1%	-	-	1%
Operating Expenses+	9.72M	7.03M	15.25M	34.41M	24.44M	16.54M	15.59M	52.16M	11.3M	16.68M
OpEx % of Revenue	44.94%	253.1%	-	-	-	84.38%	-	-	-	-
Selling, General & Admin	2.86M	1.51M	3.12M	4.29M	8.46M	6.66M	9.78M	8.21M	6.67M	7.16M
SG&A % of Revenue	13.2%	54.34%	-	-	-	33.95%	-	-	-	-
Research & Development	7.05M	5.58M	12.13M	29.37M	15.97M	4.17M	5.56M	9.97M	4.63M	9.51M
R&D % of Revenue	32.6%	200.92%	-	-	-	21.29%	-	-	-	-
Other Operating Expenses	-188K	-60.08K	0	741K	0	5.71M	249K	33.97M	0	7K
Operating Income+	-9.91M	-7.09M	-15.25M	-34.41M	-24.44M	-16.42M	-15.59M	-52.16M	-11.31M	-16.68M
Operating Margin %	-45.8%	-255.26%	-	-	-	-83.77%	-	-	-	-
Operating Income Growth %	-0.02%	0.28%	-1.15%	-1.26%	0.29%	0.33%	0.05%	-2.35%	0.78%	-0.47%
EBITDA+	-8.04M	-5.33M	-13.18M	-32.07M	-22.12M	-15.49M	-15.34M	-52.03M	-11.3M	-16.67M
EBITDA Margin %	-37.18%	-191.67%	-	-	-	-79.06%	-	-	-	-
EBITDA Growth %	0.01%	0.34%	-1.48%	-1.43%	0.31%	0.3%	0.01%	-2.39%	0.78%	-0.48%
D&A (Non-Cash Add-back)	1.87M	1.77M	2.07M	2.33M	2.32M	924K	0	124K	11K	7K
EBIT	-9.91M	-4.66M	-16.37M	-39.09M	-25.27M	-10.72M	-15.34M	-18.25M	-14.63M	-16.68M
Net Interest Income+	66.34K	52.39K	-1.11M	-427K	43K	-157K	77K	246K	911K	711K
Interest Income	69.53K	53.87K	55.75K	358K	336K	107K	77K	246K	911K	711K
Interest Expense	3.24K	1.48K	283.41K	278K	293K	264K	0	0	0	0
Other Income/Expense	8.58M	2.43M	-1.4M	-4.96M	-1.07M	-3.26M	5.12M	184K	-3.32M	3.91M
Pretax Income+	-1.32M	-4.66M	-16.65M	-39.37M	-25.51M	-19.68M	-10.47M	-51.97M	-14.63M	-12.77M
Pretax Margin %	-6.12%	-167.78%	-	-	-	-100.4%	-	-	-	-
Income Tax+	0	0	0	0	0	0	-648K	-9.54M	-1.78M	-3.2M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	0.94%	0.82%	0.88%	0.75%
Net Income+	-1.32M	-4.66M	-16.65M	-39.37M	-25.51M	-19.68M	-9.82M	-42.43M	-12.85M	-9.57M
Net Margin %	-6.12%	-167.78%	-	-	-	-100.4%	-	-	-	-
Net Income Growth %	0.87%	-2.52%	-2.57%	-1.36%	0.35%	0.23%	0.5%	-3.32%	0.7%	0.26%
Net Income (Continuing)	-1.32M	-4.66M	-16.65M	-39.37M	-25.51M	-19.68M	-9.82M	-42.43M	-12.85M	-9.57M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-9.59	-27.94	-58.96	-46.90	-14.40	-7.98	-1.60	-5.71	-1.73	-0.79
EPS Growth %	0.86%	-1.91%	-1.11%	0.2%	0.69%	0.45%	0.8%	-2.57%	0.7%	0.54%
EPS (Basic)	-9.59	-27.94	-58.96	-46.90	-14.40	-7.98	-1.60	-5.71	-1.73	-0.79
Diluted Shares Outstanding	221.2K	222.08K	364.3K	1.13M	1.76M	2.47M	6.14M	7.43M	7.44M	12.09M
Basic Shares Outstanding	221.2K	222.08K	364.3K	1.13M	1.76M	2.47M	6.14M	7.43M	7.44M	12.09M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Feb 2015	Feb 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	15.7M	8.36M	7.35M	27.97M	15.96M	62.37M	45.53M	29.29M	24.01M	22.71M
Cash & Short-Term Investments	14.69M	7.73M	6.37M	25.76M	14.24M	60.73M	43.66M	27.89M	23M	22.13M
Cash Only	1.05M	2.23M	6.37M	16.87M	14.24M	50.94M	30.34M	27.88M	23M	22.13M
Short-Term Investments	13.64M	5.49M	0	8.89M	0	9.79M	13.32M	15K	0	0
Accounts Receivable	682.99K	294.44K	587.73K	1.19M	546K	530K	548K	802K	722K	126K
Days Sales Outstanding	1.15K	3.87K	-	-	-	986.99	-	-	-	-
Inventory	69.83K	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	135.65	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	80.53K	183K	195K	768K	602K	0	0	0
Total Non-Current Assets+	14.04M	12.69M	10.43M	8.93M	6.89M	86K	83.09M	49.83M	49.29M	49.28M
Property, Plant & Equipment	55.9K	211.79K	2.18M	2.11M	2.06M	86K	315K	567K	24K	15K
Fixed Asset Turnover	3.87x	0.13x	-	-	-	2.28x	-	-	-	-
Goodwill	0	0	0	0	0	0	12.96M	8.14M	8.14M	8.14M
Intangible Assets	13.98M	11M	7.79M	6.39M	4.24M	0	69.81M	41.13M	41.13M	41.13M
Long-Term Investments	0	0	20.13K	20K	0	0	0	0	0	0
Other Non-Current Assets	0	1.48M	429.76K	417K	594K	0	0	0	0	0
Total Assets+	29.74M	21.04M	17.78M	36.9M	22.85M	62.46M	128.62M	79.12M	73.3M	71.99M
Asset Turnover	0.01x	0.00x	-	-	-	0.00x	-	-	-	-
Asset Growth %	-0.27%	-0.29%	-0.16%	1.08%	-0.38%	1.73%	1.06%	-0.38%	-0.07%	-0.02%
Total Current Liabilities+	1.3M	842K	5.19M	13.67M	7.39M	1.58M	3.26M	3.41M	1.68M	1.93M
Accounts Payable	197.03K	276.73K	2.65M	3.05M	0	115K	3.16M	1.24M	1.01M	601K
Days Payables Outstanding	382.74	1.68K	-	-	-	552.3	-	-	33.41K	-
Short-Term Debt	0	0	0	1.36M	76K	86K	104K	75K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	5.96M	607K	0	946K	0	0
Current Ratio	12.11x	9.93x	1.42x	2.05x	2.16x	39.50x	13.97x	8.59x	14.26x	11.77x
Quick Ratio	12.05x	9.93x	1.42x	2.05x	2.16x	39.50x	13.97x	8.59x	14.26x	11.77x
Cash Conversion Cycle	905.5	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.88M	115.12K	6.22M	12.18M	2.46M	5.22M	17.09M	7.76M	9.87M	3.45M
Long-Term Debt	0	0	1.25M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	71K	0	191K	410K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	16.89M	7.35M	5.51M	2.31M
Other Non-Current Liabilities	1.88M	115.12K	4.98M	12.18M	2.39M	5.22M	10K	0	4.36M	1.14M
Total Liabilities	3.18M	957.12K	11.41M	25.85M	9.86M	6.8M	20.35M	11.17M	11.56M	5.38M
Total Debt+	0	0	1.25M	1.36M	147K	86K	295K	485K	0	0
Net Debt	-1.05M	-2.23M	-5.12M	-15.51M	-14.09M	-50.86M	-30.04M	-27.39M	-23M	-22.13M
Debt / Equity	-	-	0.20x	0.12x	0.01x	0.00x	0.00x	0.01x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3053.95x	-4805.56x	-53.82x	-123.76x	-83.41x	-62.19x	-	-	-	-
Total Equity+	26.56M	20.09M	6.37M	11.04M	12.99M	55.66M	108.27M	67.95M	61.74M	66.61M
Equity Growth %	-0.11%	-0.24%	-0.68%	0.73%	0.18%	3.28%	0.95%	-0.37%	-0.09%	0.08%
Book Value per Share	120.06	90.45	17.48	9.77	7.37	22.53	17.63	9.14	8.30	5.51
Total Shareholders' Equity	26.56M	20.09M	6.37M	11.04M	12.99M	55.66M	108.27M	67.95M	61.74M	66.61M
Common Stock	49.26M	45.73M	56.79M	110.86M	137.42M	197.19M	257.99M	258.29M	261.04M	1K
Retained Earnings	-26.62M	-29.24M	-56.05M	-100.83M	-126.34M	-146.02M	-155.84M	-198.27M	-211.12M	-220.69M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	-7.89M	-6.33M	-6.04M	-6.04M	-6.04M	-6.04M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Feb 2015	Feb 2016	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-5.75M	-4.85M	-9.69M	-24.79M	-22.95M	-14.32M	-17.23M	-15.91M	-12.33M	-14.9M
Operating CF Margin %	-26.6%	-174.59%	-	-	-	-73.06%	-	-	-	-
Operating CF Growth %	0.06%	0.16%	-1%	-1.56%	0.07%	0.38%	-0.2%	0.08%	0.22%	-0.21%
Net Income	-1.32M	-4.66M	-16.65M	-39.37M	-25.51M	-19.68M	-9.82M	-42.43M	-12.85M	-9.57M
Depreciation & Amortization	1.87M	1.77M	2.07M	2.33M	2.32M	924K	0	124K	11K	7K
Stock-Based Compensation	1.24M	228.03K	719.37K	777K	1.95M	1.17M	1.34M	1.81M	913K	730K
Deferred Taxes	0	0	0	0	0	0	-648K	-9.54M	-1.83M	-3.2M
Other Non-Cash Items	-8.58M	-2.15M	1.39M	5.28M	1.51M	9.21M	-5.32M	33.94M	2.71M	-3.22M
Working Capital Changes	1.04M	-30.25K	2.77M	6.19M	-3.22M	-5.95M	-2.79M	181K	-1.28M	342K
Change in Receivables	235.78K	336.5K	-428.21K	-620K	581K	58K	-18K	-302K	80K	596K
Change in Inventory	139.07K	64.94K	0	0	0	0	0	0	0	0
Change in Payables	-69.52K	36.94K	0	0	0	0	0	0	0	0
Cash from Investing+	6.1M	6.07M	-318.26K	-9.44M	8.14M	-9.86M	-3.52M	13.15M	104K	0
Capital Expenditures	-27.97K	-203.67K	-352.33K	-534K	-319K	-69K	0	-17K	-22K	0
CapEx % of Revenue	0.13%	7.33%	-	-	-	0.35%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-7.99K	16.23K	54.2K	0	0	0	0	0	111K	0
Cash from Financing+	36.77K	-2.21K	8.83M	45.69M	13.18M	59.49M	0	304K	7.36M	14.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	36.77K	-2.21K	295.03K	798K	7.76M	158K	0	0	-141K	-967K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.82M	-5.12M	-10.05M	-25.32M	-23.27M	-14.39M	-17.23M	-15.93M	-12.36M	-14.9M
FCF Margin %	-26.92%	-184.36%	-	-	-	-73.41%	-	-	-	-
FCF Growth %	0.07%	0.12%	-0.96%	-1.52%	0.08%	0.38%	-0.2%	0.08%	0.22%	-0.21%
FCF per Share	-26.32	-23.07	-27.58	-22.39	-13.21	-5.82	-2.81	-2.14	-1.66	-1.23
FCF Conversion (FCF/Net Income)	4.35x	1.04x	0.58x	0.63x	0.90x	0.73x	1.76x	0.38x	0.96x	1.56x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-4.69%	-19.99%	-125.89%	-452.14%	-212.26%	-57.33%	-11.98%	-48.15%	-19.82%	-14.91%
Return on Invested Capital (ROIC)	-27.11%	-24.54%	-119.77%	-	-	-664.74%	-28.16%	-65.86%	-21.4%	-30.06%
Gross Margin	13.13%	-116.22%	-	-	-	61.22%	-	-	-	-
Net Margin	-611.68%	-16777.63%	-	-	-	-10039.8%	-	-	-	-
Debt / Equity	-	-	0.20x	0.12x	0.01x	0.00x	0.00x	0.01x	-	-
Interest Coverage	-3053.95x	-4805.56x	-53.82x	-123.76x	-83.41x	-62.19x	-	-	-	-
FCF Conversion	4.35x	1.04x	0.58x	0.63x	0.90x	0.73x	1.76x	0.38x	0.96x	1.56x
Revenue Growth	-51.95%	-87.15%	-100%	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Grace Therapeutics, Inc. (GRCE) grew revenue by 0.0% over the past year. Growth has been modest.

Grace Therapeutics, Inc. (GRCE) reported a net loss of $7.8M for fiscal year 2025.

Dividend & Returns

Grace Therapeutics, Inc. (GRCE) has a return on equity (ROE) of -14.9%. Negative ROE indicates the company is unprofitable.

Grace Therapeutics, Inc. (GRCE) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.